Janssen Pharmaceutica NV has described 4-amino-6-oxo-pyridazine derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, asthma and metabolic, autoimmune, liver, renal, cardiovascular and inflammatory disorders, among other disorders.
Mindset Pharma Inc. has patented indole derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of neurological disorders and psychosis, among other disorders.
Guangzhou Henovcom Bioscience Co. Ltd. has identified new imidazole TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported to be useful for the treatment of cancer, hepatic fibrosis, inflammation, osteoporosis, Alzheimer's disease, idiopathic pulmonary fibrosis, diabetic nephropathy and renal disorders, among other disorders.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described new serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer.
Levena Biopharma Co. Ltd. and Sorrento Therapeutics Inc. have synthesized antibody-drug conjugates consisting of auristatin analogues covalently linked to monoclonal antibody targeting B-cell maturation protein (BCMA) through a linker.
Les Laboratoires Servier SAS has divulged new glucagon-like peptide (GLP-1) receptor agonists reported to be useful for the treatment of obesity and diabetes.
Kancera AB has shown that its Fractalkine-blocking candidate drug may increase the efficacy of platinum-based chemotherapy and reduce tumor growth in animal models of ovarian cancer.
Impairment in the functionality of the adipose tissue is crucial for obesity-related metabolic comorbidities and may trigger the onset of type 2 diabetes. The adipose tissue has been proposed as a main contributor of circulating miRNAs (miRNAs), but has not yet been characterized for these markers.
Understanding how alternative splicing is regulated and how it contributes to disease pathogenesis might open new therapeutic options for the treatment of diabetic nephropathy (DN). Bcl-2-like protein 1 (BCL2L1), also known as BCLX, for which two alternative splicing forms (Bcl-xL and Bcl-xS) have been seen to have antagonistic effects.
RSS
